A Phase 2b multicenter dose ranging study to evaluate efficacy and safety of PF-06700841 in systemic lupus erythematosus

• Register: EUCTR
• Last refreshed on: 13 November 2023
• Main ID: EUCTR2018-004175-12-BG
• Date of registration: 30/07/2019
• Prospective Registration: Yes
• Primary sponsor: Pfizer Inc.
• Public title: A Phase 2b multicenter dose ranging study to evaluate efficacy and safety of PF-06700841 in systemic lupus erythematosus
• Scientific title: A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
• Date of first enrolment: 11/10/2019
• Target sample size: 350
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004175-12
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 4
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no

Countries of recruitment

Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czech Republic, Czechia, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Romania, Serbia, Spain, Taiwan, Ukraine, United Kingdom, United States

Contacts

• Name: Clinical Trials.gov Call Centre
• Affiliation: Pfizer Inc.

• Name: Clinical Trials.gov Call Centre
• Affiliation: Pfizer Inc.

Key inclusion & exclusion criteria

Inclusion criteria:
• Male or female participants between the ages of 18 (or the minimum country specific age of consent if >18) and 75 years, inclusive, at the time of signing the informed consent document (ICD).
o Refer to Appendix 4 for reproductive and contraceptive criteria for female participants.
• Have a clinical diagnosis of SLE according to the 1997 update on the 1982 revised American College of Rheumatology (ACR) Criteria for the Classification of SLE see Appendix 8 OR meet at least 4 of the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria see Appendix 9, including at least 1 clinical criterion and 1 immunologic criterion, at least 6 months prior to dosing of study agent.
• Have serologically positive SLE at the screening visit based on 1 of the following test results from the central laboratory during the screening period:
o ANA titer =1:80, or
o Positive anti dsDNA.
Note: The ANA and/or anti double stranded DNA (anti-dsDNA) measurement may be repeated once at the central laboratory within approximately 2 weeks of the initial value, and the value resulting from repeat testing may be accepted for enrollment eligibility if it meets the eligibility criterion.
• All participants must be currently receiving EITHER a stable dose of an immunosuppressant [methotrexate (MTX), azathioprine(AZA)/6-mercaptopurine (6-MP), leflunomide, mizoribine, mycophenolate/mycophenolic acid(MMF)] with or without antimalarials and/or corticosteroids, OR anti-malarials(hydroxychloroquine or chloroquine) in combination with corticosteroids. Antimalarial or steroid monontherapy is not permitted. If receiving antimalarials in combination with corticosteroids, the minimum dose of corticosteroids permitted as part of this combination is 5 mg prednisone daily or an equivalent dose and steroids must have been started at least 8 weeks prior to Day 1. Participants may not be receiving combinations of 2 or more immunosuppressants.
Note: Stable dose is defined as no new therapy or change in standard-of-care therapies as above within 12 weeks of Day 1 for immunosuppressives or within 2 weeks of Day 1 for corticosteroids, however brief fluctuations in therapy for toxicity are permitted (eg, holding a dose (=7 days) or temporary reduction in corticosteroids of less than 3 mg/day. See Appendix 13 for allowable stable doses.
•Have active disease defined as:
SLEDAI-2K score of =8 points at screening and at randomization and “Clinical” SLEDAI-2K score of =6 points at both screening and at randomization.
NOTE: "Clinical" SLEDAI-2K score (See Appendix 11) the SLEDAI-2K score without the inclusion of points attributable to any urine or laboratory results including immunologic measures
a. For inclusion in the study, the Clinical SLEDAI-2K calculation for entry will exclude points for: 1.Lupus Headache 2.Skin disease involving Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Erythema scores <2, 3.Arthritis scores must involve a minimum of 3 joints, both swollen and tender, 4.Mucosal ulcers which may have occurred within the previous 30 days but are not noted on exam and CLASI at the time of screening. b.On the day of randomization, a minimum of 3 joints that are both swollen and tender is required if SLEDAI Arthritis is marked PRESENT. The site should check the joint exam prior to randomization to ensure there are =3 joints that are both tender and swollen to avoid a protocol deviation. c.For SCREENING and ONSTUDY
Exclusion criteria:
• Active, severe lupus nephritis (World Health Organization Class III, IV) that requires or may require treatment with cytotoxic agents or high-dose CS are excluded. Participants with prior, controlled, renal disease that has been treated with an ACE or ARB inhibitor and immunosuppressive therapy (cyclophosphamide or mycophenolate mofetil) with serum creatinine = 2× upper limit of normal (ULN) and either residual proteinuria up to =3 g/day or a urine protein/creatinine ratio (UPCR) of = 3 mg/mg or339 mg/mmol are allowed if prior treatment has been demonstrated. Control of renal disease must be documented with at least 2 measurements of proteinuria or UPCR over the past 6 months. Participants with pure Type V membranous nephropathy must be biopsy confirmed if immunosuppressive therapy was not administered. Pfizer clinical and adjudicators will make the final decision regarding this exclusion criteria. If at all possible, biopsy results confirming the diagnosis should be available in the participant chart.
Note: The lab measurements related to lupus nephritis may be repeated once within approximately 2 weeks of the initial values, and the values resulting from repeat testing may be accepted for enrollment eligibility if they meet the eligibility criteria.
• Have severe active central nervous system (CNS) lupus (eg, BILAG A neurological disease and/or active, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia or dementia related to SLE, active psychosis, organic brain syndrome, cerebrovascular accident [CVA], cerebritis or CNS vasculitis) requiring therapeutic intervention within 60 days of Day 1. Participants with BILAG B level neurologic disease are not excluded as long as they meet all other qualifying criteria for the study.
• Have cancer or a history of cancer within 5 years of screening (other than adequately resected cutaneous basal cell, squamous cell carcinoma, or carcinoma in situ of the uterine cervix with no evidence of recurrence within the previous 3 years). If a participant is followed for a history of cancer that is considered to be treated and cured, a note from the oncologist, or specialist following the participant for recurrence noting they are aware of and agree with potential participation should be available in the source document. Potential participants who have an unacceptably high risk of tumor recurrence may be rejected by the Sponsor or their delegate. Additionally, the participant is required to comply with recommended follow up testing with their specialist of record while participating in the study.
• The following is exclusionary;
- Any history of thrombosis (venous or arterial) or cerebrovascular ischemic event (stroke or transient ischemic attack [TIA]) within the last 6 months.
- A history of an ischemic cerebrovascular event (stroke, TIA) within the past 12 months unless these were caused by known antiphospholipid syndrome and the participant has been adequately anticoagulated (and will continue on anticoagulation per guidelines) according to current guidelines for at least 6 months without a recurrence of any thrombotic event.
• Any history of a pulmonary embolus, unless these were caused by known antiphospholipid syndrome and the participant has been adequately anticoagulated (and will continue on anticoagulation per guidelines) according to current guidelines for at least 6 months without a recurrence of any thrombotic event.
Note:

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Systemic Lupus Erythematosus (SLE)
MedDRA version: 21.1 Level: PT Classification code 10042945 Term: Systemic lupus erythematosus System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

Intervention(s)

Product Name: PF-06700841
Product Code: PF-06700841 5mg
Pharmaceutical Form: Tablet
INN or Proposed INN: brepocitinib
Current Sponsor code: PF-06700841
Other descriptive name: PF-06700841-15
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use

Product Name: PF-06700841
Product Code: PF-06700841 25mg
Pharmaceutical Form: Tablet
INN or Proposed INN: brepocitinib
Current Sponsor code: PF-06700841
Other descriptive name: PF-06700841-15
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use

Primary Outcome(s)

Secondary Objective: - To assess time to first severe flare in PF-06700841 treated participants relative to placebo.
- To assess attainment of low disease activity state of 3 QD dose levels of PF-06700841 compared to placebo in participants with active SLE.
- To compare the corticosteroid use (prednisone or equivalent) in PF-06700841 treated participants relative to placebo.
- To evaluate the efficacy of PF-06700841 compared to placebo in participants with active SLE and with sustained reduction of oral corticosteroids.
- To evaluate the Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) score in the subset of participants with baseline CLASI-A score =10 in PF-06700841 treated participants relative to placebo.
- To evaluate the effect on fatigue of PF-06700841 treated participants relative to placebo.

Please refer to protocol B7931028 section 3 for a full list of secondary objectives.

Timepoint(s) of evaluation of this end point: Week 52

Main Objective: To evaluate the efficacy of 3 once daily (QD) dose levels of PF-06700841 compared to placebo in participants with active SLE.

Primary end point(s): Proportion of participants achieving the Systemic Lupus Erythematosus Responder Index (SRI) change of 4 (SRI-4) at Week 52.

Secondary Outcome(s)

Timepoint(s) of evaluation of this end point: Individual timepoints are included in each secondary endpoint bullet point above.

Secondary end point(s): • Time to first severe flare as measured by the modified Safety of Estrogen in Lupus: National Assessment (SELENA) Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index (mS-SFI).
• Proportion of participants achieving the Lupus Low Disease Activity State (LLDAS) at Week 52.
• Proportion of participants achieving a reduction in prednisone (or equivalent) dose to = 7.5 mg/day at week 52 and sustained for 12 weeks prior to Week 52, in the subset of participants on prednisone >7.5 mg/day (or equivalent) at baseline.
• Proportion of participants achieving SRI-4 response with dose of prednisone (or equivalent) reduced to =7.5 mg/day and
sustained for 12 weeks at Week 24 and Week 52, in the subset of
participants with prednisone dose >7.5 mg/day (or equivalent) at
baseline.
• Proportion of Participants with Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI-A) Total Activity Score =10 at Baseline with =50% Reduction in CLASI-A Total Activity Score
• Change from baseline in the total scores of Functional Assessment of Chronic Illness Therapy Fatigue (FACIT F) at Week 52.
• Change from baseline in the individual domain scores of the Lupus Quality of Life (LupusQoL) at Week 52.
• Incidence of treatment-emergent adverse events (AEs)
• Incidence of serious AEs (SAEs) and AEs leading to discontinuation.
• The incidence of clinically significant abnormalities in vital signs and ECGs.
• The incidence of clinically significant abnormalities in clinical laboratory values.

Separate blinded adjudication committees consisting of independent external experts who will be responsible for the ongoing review of the following efficacy and safety endpoints: 1) BILAG, SLEDAI and associated data; 2) Severe Flare; 3) Cardiovascular and thromboembolic events; 4) Malignancy; and 5) Opportunistic infections.

Secondary ID(s)

NCT03845517

2018-004175-12-BE

B7931028

Source(s) of Monetary Support

Pfizer Inc.

Ethics review

Status: Approved
Approval date: 20/09/2019
Contact: